Ezetimibe and recent clinical trials: A look on the bright side

Expert Opinion on Drug Safety

Volumn 9, Issue 4, 2010, Pages 511-514

  Ahmed, Mohamed H ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

clinical trials; ezetimibe; hyperlipidemia; non alcoholic fatty liver disease

Indexed keywords

C REACTIVE PROTEIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; DELAYED RELEASE FORMULATION; HYPOCHOLESTEROLEMIC AGENT;

ACUTE CORONARY SYNDROME; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GALLSTONE; HEART INFARCTION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; REVIEW; RISK REDUCTION; STROKE; UNSPECIFIED SIDE EFFECT; BLOOD; CORONARY DISEASE; DELAYED RELEASE FORMULATION; DRUG COMBINATION; HYPERCHOLESTEROLEMIA; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERCHOLESTEROLEMIA; NIACIN; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMVASTATIN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 77953730404     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740331003702376     Document Type: Review

References (19)

1. Montecucco F, Quercioli A, Mach F. Ezetimibe/simvastatin. Expert Opin Drug Saf 2009;8:715-725
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-732
3. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-2122
4. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-1443
5. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
6. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92
7. Mathur A, Walker JJ, Al-Azzawi HH, et al. Ezetimibe ameliorates cholecystosteatosis. Surgery 2007;142:228-233
8. Wang HH, Portincasa P, Mendez-Sanchez N, et al. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 2008;134:2101-2110
9. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in Type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008;52:2198-2205
10. Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 2009;49:838-847
11. Landray M, Baigent C, Leaper C, et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 2006;47:385-395
12. Targher G, Bertolini L, Padovani R, et al. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in dietcontrolled Type 2 diabetic patients. J Endocrinol Invest 2006;29:55-60 (Pubitemid 43355836)
13. Targher G, Bertolini L, Rodella S, et al. Non-alcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in Type 2 diabetic patients. Diabetes Care 2007;30:2119-2121 (Pubitemid 47219432)
14. Zheng S, Hoos L, Cook J, et al. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 2008;584:118-124
15. Deushi M, Nomura M, Kawakami A, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007;581:5664-5670
16. Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of hepatic neiman-pick C1-like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab 2009. [Epub ahead of print]
17. Buchanan C, Smith L, Corbett J, et al. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006;6:770-774
18. Alsheikh-Ali AA, Karas RH. Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: a post-marketing analysis. J Clin Lipidol 2009;3(2):138-142
19. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008;359:1357-1366 Affiliation Mohamed H Ahmed MD PhD